Suboxone is the brand name of combination of Buprenorphine and Naloxone, manufactured by Indivior, Inc., and used in the treatment of opioid dependence. In January of 2022, the FDA issued a drug safety communication about long term Suboxone sublingual film use and the increased risk of serious dental problems.

FDA ordered that a new warning about the risk of dental problems be added to the Suboxone prescribing information and patient medication guide. In June of 2022, a warning about the increased risk of dental problems was finally added to the prescribing information.